Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-26,696
Closed -$1.77M 448
2025
Q4
$1.77M Buy
+26,696
New +$1.73M 0.04% 326
2025
Q1
Sell
-2,702
Closed -$210K 841
2024
Q4
$210K Buy
+2,702
New +$200K 0.01% 769
2023
Q1
Sell
-1,880
Closed -$210K 961
2022
Q4
$213K Sell
1,880
-3,327
-64% -$365K ﹤0.01% 770
2022
Q3
$419K Sell
5,207
-878
-14% -$74.4K 0.01% 845
2022
Q2
$454K Buy
6,085
+2,785
+84% +$254K 0.01% 610
2022
Q1
$422K Buy
3,300
+976
+42% +$107K 0.01% 590
2021
Q4
$312K Buy
2,324
+680
+41% +$97.7K 0.01% 683
2021
Q3
$225K Sell
1,644
-12,088
-88% -$1.52M 0.01% 930
2021
Q2
$1.47M Buy
13,732
+11,124
+427% +$1.07M 0.06% 312
2021
Q1
$234K Sell
2,608
-17,392
-87% -$1.63M 0.01% 886
2020
Q4
$1.85M Buy
+20,000
New +$1.79M 0.18% 141
2018
Q4
Sell
-15,200
Closed -$549K 114
2018
Q3
$549K Buy
+15,200
New +$471K 0.2% 98

Other funds holding DXCM

Maven Securities's DXCM Position: Q1 2026 in Review

Maven Securities sold out of DexCom (DXCM) in Q1 2026, closing a stake of 26,696 shares — an estimated $1.77M sold.

Maven Securities first reported a position in DXCM in Q3 2018 and held it in 12 quarters. The position peaked at $1.85M in Q4 2020. 962 funds tracked by Wall St. Rank hold DXCM as of Q1 2026.

  • Maven Securities reported no remaining DexCom position as of Q1 2026 after selling out during the quarter.
  • Maven Securities sold 26,696 DexCom shares in Q1 2026, an estimated $1.77M.
  • Maven Securities first reported a position in DexCom in Q3 2018 and held it in 12 quarters.
  • Maven Securities's DexCom position peaked at $1.85M in Q4 2020.
  • 962 funds tracked by Wall St. Rank held DexCom as of Q1 2026.

Based on Maven Securities's 13F filing for Q1 2026, filed 15 May 2026.